Business
Bruker Reports First Quarter 2025 Financial Results
Q1 2025 revenues of $801.4 million, up 11.0% year-over-year; organic revenue up 2.9%, and constant-exchange rate (CER) revenue up 12.5%; Bruker Scientific
About this update from Bruker Corporation
[{"type":"text","content":"\n\n Q1 2025 revenues of $801.4 million, up 11.0% year-over-year; organic revenue up 2.9%, and constant-exchange rate (CER) revenue up 12.5%; Bruker Scientific Instrument (BSI) segment organic revenue up 5.1% \n\n\nQ1 2025 GAAP diluted EPS $0.11; non-GAAP diluted EPS $0.47, down 11.3% yoy on M&A headwinds\n\n\nGuidance on organic revenue and EPS adjusted for US policy changes and tariff headwinds. Updated FY 2025 guidance: \n\n\nRevenue $3.48 to $3.55 billion, up 3.5% to 5.5%, incl. organic growth of 0% to 2%\n\n\nNon-GAAP EPS $2.40 to $2.48, growth of 0% to 3% yoy\n\n\n\n\n BILLERICA, Mass.--(BUSINESS WIRE)--\nBruker Corporation (Nasdaq: BRKR) today announced financial results for its first quarter ended March 31, 2025.\n\nFrank H. Laukien, Bruker’s President and CEO, commented: “Bruker had a solid start to 2025 with double-digit reported and CER revenue growth, 5.1% organic revenue growth in our BSI segment, and better operating margin performance than expected - all on strong execution, despite uncertainties in key markets. In Q1 and April, we launched key products in spatial biology, NMR, microbiology and molecular diagnostics. Proactive cost management helped drive organic operating margin expansion, partially offsetting the expected Q1 margin headwinds from our strategic acquisitions in Q2 of 2024.”\n\nHe continued: “It has become evident that academic market and tariff dynamics will have a meaningful impact on our financial performance in 2025, and accordingly we are lowering our organic revenue growth and non-GAAP EPS guidance for the full year. With additional cost and pricing initiatives, as well as supply network re-engineering, we anticipate that we will be able to mitigate slightly more than half of the new headwinds in 2025. We expect to resume our planned margin expansion and rapid EPS growth in 2026 and beyond.”\n\nFirst Quarter 2025 Financial Results\n\nBruker’s revenues for the first quarter of 2025 were $801.4 million, an increase of 11.0% compared to $721.7 million in the first quarter of 2024. In the first quarter of 2025, revenues increased 2.9% organically year-over-year, with constant-exchange rate (CER) revenue growth of 12.5%. Revenue growth from acquisitions was 9.6%, while foreign currency translation had an unfavorable impact of 1.5%.\n\nFirst quarter 2025 Bruker Scientific Instruments (BSI) revenues...